US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

PT-141 · cycle length · research use only

How long is a PT-141 cycle? It's the on-demand exception — there's a per-use cap, not a cycle.

Search 'PT-141 cycle length' and you'll get the same on/off framing people apply to BPC-157 or a growth-hormone secretagogue — run it for a block of weeks, then rest. For PT-141 (bremelanotide) that framing is a category error, but in the opposite direction from a metabolic agonist like retatrutide. Retatrutide isn't cycled because it's studied as continuous chronic therapy; PT-141 isn't cycled because it's the reverse — an acute, on-demand compound taken per use rather than accumulated daily. The FDA-approved label for the injectable form (Vyleesi) makes that explicit: administer at least 45 minutes before anticipated activity, with practical onset commonly in the 30-to-60-minute range, a plasma peak near one hour and a mean terminal half-life of about 2.7 hours. Because the melanocortin effect can outlast the plasma clock (duration up to ~24 hours), the label doesn't define a 'cycle' at all — it sets frequency caps: no more than one dose per 24 hours, and no more than eight doses per month. That per-use limit is the closest thing PT-141 has to a schedule. This page reproduces the label pharmacology as a research reference, explains why the cycling concept doesn't transfer, and notes how the nasal route differs from the studied subcutaneous data. It is a summary of published label data, not a human-use protocol, and not dosing or medical advice.

PT-141 nasal spray — $69.99How long does PT-141 take to work

'Cycling' assumes daily accumulation — PT-141 doesn't work that way

The on/off cycling idea comes from compounds you dose every day and build a steady-state level with: repair peptides (cycled out of caution, no long-term human data) or GH secretagogues (pulsed to preserve receptor responsiveness). PT-141 is neither. It's a melanocortin agonist taken acutely, before an occasion, and cleared within hours. There is no accumulating blood level to 'cycle off' from, so importing a weeks-on/weeks-off block from a daily peptide misreads what the compound is.

How a daily-peptide cycle differs →

The real 'schedule': a per-use frequency cap, not a cycle

The Vyleesi label doesn't specify a cycle length because there isn't one — instead it caps how often the compound is used: no more than one dose in any 24-hour period, and no more than eight doses per month. That is a genuine, published structure, but it's a maximum-use limit rather than an on/off loop. Reading 'eight per month' as anything other than a ceiling — for example, as a schedule to hit — misstates what the label says.

PT-141 dosage reference →

The pharmacology fits an acute, single-window use

Plasma peak (Tmax) sits near one hour, and the mean terminal half-life is about 2.7 hours (range roughly 1.9–4.0). A compound cleared on that timescale doesn't build a maintenance concentration across days the way a cycled peptide does. The melanocortin effect can extend up to ~24 hours, which is why the label frames use around a single anticipated window and then a mandatory gap — the opposite of continuous coverage.

PT-141 half-life explained →

Why the caps exist: melanocortin effect outlasts the plasma clock

The reason the label imposes a per-day and per-month ceiling is that the biological effect can persist well beyond the point where the compound has cleared plasma. Stacking doses inside that window doesn't extend a 'cycle' — it risks compounding melanocortin-pathway effects (the label also notes transient blood-pressure changes and, with frequent/daily use in studies, focal hyperpigmentation). The structure is built around spacing single uses apart, not running a continuous block.

PT-141 adverse-event profile →

Nasal route: Titan's format, and what the data does (and doesn't) cover

Titan stocks PT-141 as a nasal spray. The published pharmacokinetics and the frequency caps above come from the subcutaneous (injectable) label — there is no separate published PK table for an intranasal PT-141 product, so the timing figures are the injectable reference, not a nasal-specific measurement. The honest position for a research reference is to state that plainly rather than imply a nasal 'cycle' exists where no nasal schedule has been characterised.

PT-141 nasal spray sourcing →

Research-use framing

Everything here summarises the published FDA label and melanocortin pharmacology reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human use, and not a claim of efficacy or an optimal schedule in people. Titan supplies PT-141 strictly as a research reagent, not for human or animal consumption, and nothing on this page is medical or dosing advice.

Lab testing & COA workflow →

The detail, in plain terms

PT-141 'cycle length', separated into evidence and assumption.

A plain-terms split between what the melanocortin-agonist label actually establishes about PT-141 use and the on/off 'cycle' assumptions imported from daily-dosed peptide classes. The label figures are on-demand, per-use data; the 'cycle' figures have no basis for an acute compound. Reproduced as a research reference, not a human-use schedule.

Validated 'cycle length'
None. PT-141 is an on-demand melanocortin agonist, not a daily accumulator — the label defines per-use limits, not an on/off cycle.
The real published structure
A frequency cap: no more than one dose per 24 hours and no more than eight doses per month (Vyleesi/bremelanotide label).
Timing of a single use
Administered ~45 minutes before anticipated activity; practical onset ~30–60 minutes; plasma peak (Tmax) near 1 hour.
Half-life
Mean terminal ~2.7 hours (range ~1.9–4.0) — cleared in hours, so no across-days maintenance level builds.
Duration of effect
Can extend up to ~24 hours; the melanocortin effect outlasting the plasma clock is why the 24-hour spacing cap exists.
Reason peptides get cycled (for contrast)
Repair peptides: caution (no long-term data). GH secretagogues: receptor resensitisation. PT-141 accumulates nothing to cycle off.
Route caveat
PK and caps are from the subcutaneous label; there is no separate published intranasal PT-141 PK table. Nasal figures are the injectable reference.

Questions researchers ask

Before you order.

How long should a PT-141 cycle be?
The premise doesn't fit the compound. PT-141 (bremelanotide) is an on-demand melanocortin agonist taken acutely before an occasion, not a daily peptide you build a steady level with — so there is no 'cycle length' to run. The FDA-approved label defines use through frequency caps instead: no more than one dose per 24 hours and no more than eight per month. Any 'X weeks on, then off' figure you see for PT-141 is borrowed from repair or growth-hormone peptides and has no basis for an acute compound. This page is a research reference summarising label data, not a human-use schedule.
Do you have to cycle off PT-141?
There is nothing to cycle off. Because PT-141 is cleared within hours (terminal half-life ~2.7 hours) and taken per use rather than daily, it doesn't accumulate a maintenance concentration the way a cycled peptide does. The published structure that does exist is a per-use ceiling — one dose per 24 hours, eight per month on the label — which is a spacing limit between single uses, not an on/off block. Nothing here is medical advice; it summarises what the label reports.
How often can PT-141 be used according to the label?
The Vyleesi/bremelanotide label caps use at a maximum of one dose in any 24-hour period and no more than eight doses per month. It also frames each use as taken at least 45 minutes before anticipated activity. Those are maximum-frequency limits, not a target schedule to hit — and they exist because the melanocortin effect can last up to 24 hours, longer than the compound stays in plasma. This is reproduced as a research reference, not a dosing instruction.
Why isn't PT-141 cycled like BPC-157 or CJC-1295/ipamorelin?
Because those peptides are dosed daily and build a steady-state level, which is what makes an on/off 'cycle' meaningful — BPC-157 is cycled out of caution (no long-term human data), and GH secretagogues like CJC-1295/ipamorelin are pulsed to preserve receptor responsiveness. PT-141 is acute and on-demand: it clears in hours and accumulates nothing, so there's no steady level to interrupt. Same word, 'cycle', but a fundamentally different underlying model — which is why the framing transfers poorly.
Does the nasal spray have its own cycle or frequency data?
No separate published pharmacokinetic table exists for an intranasal PT-141 product; the timing figures and frequency caps above come from the subcutaneous (injectable) label. The honest research-reference position is to treat those as the injectable reference rather than assume a nasal-specific 'cycle' or schedule has been characterised. Titan stocks PT-141 as a nasal spray and supplies it strictly as a research-use-only reagent.
Is PT-141 approved for human use?
Bremelanotide is FDA-approved as an injectable product under a specific brand for a specific indication, but Titan Peptide Lab supplies PT-141 strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic or preventative use. The label pharmacology summarised here is a research reference, not medical or dosing advice.

Related reading

Before you check out.